Targeted News Service

AstraZeneca: Tagrisso (osimertinib) Demonstrated Overwhelming Efficacy Benefit for Patients With Unresectable, Stage III EGFR-Mutated Lung Cancer in LAURA Phase III Trial
February 20, 2024

WILMINGTON, Delaware, Feb. 20 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release:

Positive high-level results from the LAURA Phase III trial showed AstraZeneca's TAGRISSO(R) (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival (PFS) for patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after chemoradi . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your Affiliation	Government Newspaper / Media Business Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions or comments:

Click here for more information about our products

Existing Customer Login

Targeted News Service Document Request Form